Rob holds a bachelor’s degree in chemical engineering (North Carolina State University) and a Ph.D. in biomedical engineering (Duke University). He spent over 10 years in the regenerative medicine industry, where he led the development of a cell-based process for manufacturing tissue-engineered blood vessels from the small-scale, pre-clinical phase to the industrial-scale, GMP-compliant phase. For the past 2 years, he’s been the Head of Science at Jellatech, where he is leading the development of a platform technology for producing complex animal proteins, such as collagen, directly from animal cells. In these positions, he has played a key role in fundraising from pre-seed through IPO, specifically in demonstrating the promise of the science/technology and in presenting long-term company strategy. Overall, Rob has a passion for building and developing technical teams to address global challenges as a part of dynamic, emerging companies.
Panel Discussion: Innovative financing mechanisms for industrial scale of alternative proteins
With financing and transaction activity in the alternative proteins industry slowing in 2022 due to the unfavourable global economic environment, there has never been a more challenging time in...
Europe's Meeting Place For Alternative Protein Production Solutions